MID 41. Antiretroviral Therapy. The Life Cycle of HIV-1. Nucleoside Analog RT Inhibitors. Antiretroviral Agents
|
|
- Edmund Wheeler
- 6 years ago
- Views:
Transcription
1 Antiretroviral Agents Antiretroviral Therapy Scott. Hammer,.D. Every step in viral life cycle is a potential antiviral target Currently there are 7 classes of FDA approved agents - Nucleoside analog reverse transcriptase inhibitors (NsTs) - Nucleotide analog reverse transcriptase inhibitor (NtT) - Non-nucleoside reverse transcriptase inhibitors (NNTs) - Protease inhibitors (Ps) - Fusion inhibitor (enfuvirtide)» Entry inhibitor which targets the virus - CC5 antagonist inhibitors (maraviroc)» Entry inhibitor which targets the host - ntegrase inhibitors (raltegravir) Drugs must be used in combination to be effective - This has led to dramatic reductions in morbidity and mortality where AT has been introduced effectively Current therapies are imperfect - Toxicities - Drug resistance ZD monox Alternative NT monox Combination NT x ntroduction of NNT s Antiretroviral resistance Pathogenetic concepts Evolution of Antiretroviral Therapy End of ZD monox era Benefit of combination x proven ntroduction of protease inhibitors e-emergence of NNT s ntroduction of viral load monitoring Elucidation of viral dynamics nowledge of viral reservoirs Capacity for immune restoration mportance of chemokine receptors eductions in morbidity & mortality ntroduction of resistance testing etabolic complications of therapy eality of new classes of agents Swings in approach to x A rollout in developing countries Nucleoside (ns) and Nucleotide (nt) Analog T nhibitors Zidovudine (ZD, AZT) Didanosine (dd) Zalcitabine (ddc) Stavudine (d4t) nst s amivudine (3TC) Abacavir (ABC) Emtricitabine (FTC) Tenofovir disoproxil fumarate (TDF) ntt N.B.: Four fixed dose combinations are approved: ZD + 3TC (Combivir ); ZD + 3TC + ABC (Trizivir ); 3TC + ABC (Epzicom ); FTC + TDF (Truvada ) The ife Cycle of H-1 Structural Protein and Enzyme Precursors Nucleoside Analog T nhibitors iral NA iral DNA iral NA 1. Binding and infection 2. everse transcription and integration of viral DNA 3. Transcription and translation 4. odification and assembly 5. Budding and final assembly Zidovudine Didanosine
2 Nucleoside Analog T nhibitors Non-Nucleoside T nhibitors First class of anti-h agents developed Active vs. H-1 and H-2 Need to undergo intracellular anabolic phosphorylation to triphosphate form of the drug or metabolic intermediate to be active vs. H echanism - NT-TP s inhibit the H T by competing with normal nucleoside triphosphates for incorporation into growing proviral DNA chain - iral DNA chain elongation terminated» Absence of 3 -OH group on sugar moiety prevents addition of another nucleotide - iral replication ceases Nevirapine Efavirenz Nucleotide Analog T nhibitors Tenofovir disoproxil fumarate (TDF) - A prodrug - Contains a phosphate group so only needs to be diphosphorylated intracellularly to be active» Tenofovir-diphosphate is the active moiety - Competiive inhibitor of H T Non-Nucleoside T nhibitors Second class of anti-h agents developed Potent but subject to rapid emergence of resistance Active vs. H-1 (except Group O) nactive vs. H-2 Parent molecules are the active moieties echanism - NNT s inhibit the H-1 T by binding to hydrophobic pocket on the enzyme close to the active site» ay lock active site in an inactive conformation Non-Nucleoside T nhibitors H T: Structure Nevirapine (NP) Delavirdine (D) Efavirenz (EFZ) Etravirine (ET) Huang H, Chopra, erdine G & Harrison SC: Science 1998;282:
3 NNT s: Drug nteractions etabolized by CYP3A4 isozyme of hepatic p450 system NP and EFZ are inducers of CYP3A4 D is an inhibitor of CYP3A4 Potential for major drug interactions with numerous H (esp. P s) and non-h agents Do not prescribe without first checking for potential drug interactions - ay be contraindications or need for dose adjustment(s) Protease nhibitors Third class of anti-h agents developed Potent - evolutionized therapy following introduction in 1996 Active vs. H-1 and H-2 echanism - P s inhibit the H protease by binding to active site and preventing the cleavage of gag and gag-pol precursor polyproteins - irions are produced but they are incomplete and noninfectious Protease nhibitors Protease Structure: utations Associated With educed in vitro Susceptibility to opinavir Saquinavir (SQ)* itonavir (T) ndinavir (D)* Nelfinavir (NF) Amprenavir (AP)* opinavir/ritonavir (P/r)* Atazanavir (AT)* Fosamprenavir (fos-ap)* Tipranavir (TP)* Darunavir (D)* *Typically prescribed with low-dose ritonavir for pharmacologic boosting. opinavir is coformulated with ritonavir. Protease nhibitors P s: Drug nteractions etabolized by CYP3A4 isozyme of hepatic p450 system nhibit CYP3A4 to varying degrees - itonavir is one of the most potent CYP3A4 inhibitors known» Basis for using low-dose T as pharmacoenhancer of other P s» One approved P, P, is coformulated with T Potential for major drug interactions with numerous H (esp. NNT s) and non-h agents Do not prescribe without first checking for potential drug interactions - ay be contraindications or need for dose adjustment(s) ndinavir itonavir
4 H Entry Target cell membrane ENF Enfuvirtide nhibition of H Fusion gp41 H1 X X H2 iral membrane eceptor Binding Fusion ntermediate X H2- Zipping X Six-Helix Bundle Formation ENF nhibition Enfuvirtide (Fusion nhibitor): echanism of Action CC5 Antagonist: araviroc odel for H-Cell Fusion Percentage of H Co-receptor Usage Target cell membrane gp41 H1 Study/Source Homer cohort 1 C & W cohort 2 Demarest 3 Population Naive Naive Naive N % 81% 88% X4 <1% <1% 0% 5/X4 18% 19% 12% H2 TOO 1/2 4 Experienced % 4% 34% iral membrane eceptor Binding Fusion ntermediate H2- Zipping Six-Helix Bundle Formation iroogic 5 ACTG Experienced Experienced > % 49% *This table may not include all available reported data. ajority of data are generated in the developed world (subtype B) 2% 4% 50% 47% 1 Brumme Z, et al. J nfect Dis. 2005;192: oyle GJ, et al. J nfect Dis. 2005;191: Demarest J, et al. CAAC Abstract H Whitcomb J, et al. CO Abstract Paxinos EE, et al. CAAC Abstract Wilkin T, et al. CO Abstract 655.
5 CC5 antagonist CC5 Antagonists Target H Binding and Fusion With CD4+ T Cells ntegrase nhibitor: altegravir CD4 CC5 T-cell surface Binding of CC5 Antagonist Causes a Conformational Change H ntegration CD4 CC5 CC5 antagonist T-cell surface H-1 gp41 gp120 altegravir: An H-1 ntegrase nhibitor N N O O H N O N N O - + H N O F CD4 CC5 CC5 antagonist T-cell surface echanism of action - nhibits DNA strand transfer from provirus into host cell genome a key step in viral integration process Potent in vitro activity» C 95 = 33 n ± 23 n in 50% human serum» Active against: - multi-drug resistant H-1 - CC5 and CXC4 H-1» H resistant to raltegravir remains sensitive to other ATs» Synergistic in vitro with all ATs tested
6 Nucleoside T s Zidovudine (ZD) Didanosine (dd) Zalcitabine (ddc) Stavudine (d4t) amivudine (3TC) Abacavir (ABC) Emtricitabine (FTC) Nucleotide T Tenofovir DF (TDF) Antiretroviral Agents Approved in the U.S. Non-Nucleoside T s Nevirapine (NP) Delavirdine (D) Efavirenz (EFZ) Etravirine (ET) ntegrase nhibitor altegravir (A) N.B.: Six fixed-dose combinations are approved: ZD + 3TC (Combivir ); ZD + 3TC + ABC (Trizivir ); ABC + 3TC (Epzicom ); FTC + TDF (Truvada ); P + T (aletra ); TDF + FTC + EF (Atripla ) Protease nhibitors Saquinavir (SQ) itonavir (T) ndinavir (D) Nelfinavir (NF) Amprenavir (AP) opinavir/r (P/r) Atazanavir (AT) Fosamprenavir (Fos-AP) Tipranavir (TP) Darunavir (D) Fusion nhibitor Enfuvirtide (T-20) CC5 Antagonist araviroc (C) ationale for nitiation of Therapy Before CD4 Cell Counts Fall to 350/μ - Uncontrolled H replication and resultant immune activation associated with non-ads illnesses» Cardiovascular» Hepatic» enal» alignancies - Patients with CD4 counts >350/μ and H-1 NA levels >400 copies/m have greater morbidity and mortality than those with viral suppression» Definition of H-related disease progression should be revisited - Potential for decreased horizontal H-1 transmission Non-ADS Conditions Since 2006, a number of non-ads conditions have been described to be associated with uncontrolled H-1 viremia, even in persons with relatively well preserved CD4 cell counts (e.g., >350/mm 3 ) - Cardiovascular events - Hepatic disease - enal disease - alignancies Direct effect of H-1 on organ systems, associated immune activation and/or other mechanisms may be involved Active area of investigation edefining H-related disease progression and influencing decision of when to start AT When to Start Therapy: Balance Tipping in Favor of Earlier nitiation Drug toxicity Preservation of limited x options ater Potency, durability, simplicity and safety of current regimens mproved formulations and P Enhanced adherence Diminished emergence of resistance ore treatment options ecognition of deleterious effect of uncontrolled viremia at all CD4 levels Earlier nitiation of Therapy in Established H nfection: Considerations Patient s disease stage - Symptomatic status - CD4 cell count - Plasma H-1 NA level - Presence of, or risk factors for, non-ads conditions» Cardiovascular, hepatic and renal disease Patient s commitment to therapy Philosophy of treatment - Pros and cons of early intervention When to Start Antiretroviral Therapy easure ecommendation Comments Symptomatic H disease Therapy recommended Asymptomatic H disease CD4 <350/µl Therapy recommended ecommendation strengthened since 2006 CD4 >350 Therapy should be considered and decision individualized Examples Correlates of faster H disease progression: High viral load (>100,000 NA copies/ml) apidly declining CD4 (>100/µl per year) Coexistent conditions influenced by uncontrolled viremia: Presence of, or high risk for, cardiovascular disease Active HB or HC coinfection H-associated nephropathy
7 Choice of nitial egimen At baseline: Evaluate for hepatitis B or C coinfection, diabetes mellitus, hyperlipidemia, coronary artery disease, renal disease, other comorbid conditions and medications Perform resistance testing Assess for pregnancy or risk thereof egimen: Nonnucleoside reverse transcriptase inhibitor (NNT)-based or itonavir (r)-boosted protease inhibitor (P)-based Either (NNT or P/r) combined with a dual nucleoside/nucleotide reverse transcriptase inhibitor (nt) component Antiretroviral Therapy Failure Clinical - Disease progression» Needs to be distinguished from immune reconstitution syndrome mmunologic - CD4 cell count decline irologic - Plasma H-1 NA rise Choice of nitial egimen (cont d) Component Drugs Comments NNT component efavirenz EF: teratogenic in 1 st trimester NP (alternative): increased risk of hepatotoxicity in women with CD4 >250/µl and men with CD4 >400/µl P/r component Dual nt component lopinavir/r, atazanavir/r, fosamprenavir/r, darunavir/r or saquinavir/r tenofovir/emtricitabin e or abacavir/lamivudine AT/r: diminished hyperlipidemic potential; care with antacids D/r: important role in treatment-experienced patients ZD/3TC: alternative ABC: Screen for HA-B*5701 to decrease risk of HS;?increased risk of cardiovascular disease ABC/3TC:?efficacy when viral load >100,000 c/ml easons for Drug Failure esistance Adherence Pharmacologic factors nsufficiently potent regimens Sanctuaries Cellular mechanisms of resistance Host immune status Simplification of Therapy D ZD 3TC EF/TDF/FTC imitations of Currently Available Agents Some regimens remain complex - Particularly for treatment experienced patients or those who may have primarily acquired drug resistant virus» Approximately 10% of new infections are with drug resistant virus in the U.S. and Europe Negative effects on quality of life Toxicities, particularly metabolic - Hyperlipidemia, fat redistribution, insulin resistance, decreased bone density, mitochondrial dysfunction Drug class cross resistance Drug interactions (esp. for NNTs and Ps) Submaximal potency Cost
8 Antiretroviral Therapy elated ipodystrophy ipoatrophy ipoaccumulation H esistance: Underlying Concepts mplications - esistance mutations may exist before drug exposure and may emerge quickly after it is introduced - Drugs which develop high level resistance with a single mutation are at greatest risk» e.g., 3TC, FTC, NNT s (nevirapine, efavirenz) - esistance to agents which require multiple mutations will evolve more slowly - Partially suppressive regimens will inevitably lead to emergence of resistance - A high genetic barrier needs to be set to prevent resistance» Potent, combination regimens allon PWG, Cooper DA and Carr A: H edicine 2001;2: utations Selected by nts/ntts H esistance: Underlying Concepts Zidovudine E D D N 118 T W YF QE E D T Genetic variants are continuously produced as a result of high viral turnover and inherent error rate of T - utations at each codon site occur daily» Survival depends on replication competence and presence of drug or immune selective pressure - Double mutations in same genome also occur but 3 or more mutations in same genome is a rare event - Numerous natural polymorphisms exist Stavudine D Didanosine Zalcitabine Abacavir E amivudine 44 D Emtricitabine N T D Y 115 F W YF QE Tenofovir 65 Pre-existence of esistant utants The Two Principal echanisms of esistance of H to Nucleoside Analogues iral replication cycles: /day T error rate: /base/cycle H genome: 10 4 bp Every point mutation occurs times/day Clavel F et al: N Engl J ed 2004;350:
9 utations Selected by NNTs utations Selected by Ps (cont d) ulti-nnt esistance ulti-nnt esistance: Accumulation of utations N Y G A C SA Y 188 Nelfinavir D N A F N AFT DS T S Nevirapine Y Y G N A C CH A Saquinavir/ ritonavir G A G T S AF TS Delavirdine Y Y P N C Tipranavir /ritonavir E Q H T N F G T AE P T D Efavirenz Y Y G P N C SA H echanism of esistance of H to Nonnucleoside everse-transcriptase nhibitors H-1 Protease Dimer Binding with a Protease nhibitor (Panel A) and a Drug-Sensitive (Wild-Type) Protease Juxtaposed against a Drug-esistant Protease (Panel B) Clavel F et al: N Engl J ed 2004;350: Clavel F et al: N Engl J ed 2004;350: utations Selected by Ps utations in the gp41 Envelope Gene Associated With esistance to Enfuvirtide Atazanavir +/-ritonavir G FC E E G F D A G Q Y E CSTA T F TA T N ATF S Enfuvirtide G Fosamprenavir ritonavir F S AFT S Darunavir/ ritonavir G S F 89 G 36 D S A E Q 39 Q N N First heptad repeat (H1 egion) H T D ndinavir/ ritonavir A G T SA AFT opinavir/ ritonavir F A G F F A A P T S AFT S TS
10 araviroc esistance Csens virus Cres virus Adults and Children Estimated to be iving with H in 2007 Free receptor wt gp120 gp120 binding site on CC5 High affinity utated gp120 recognizes CC5 Cres gp120 differently High affinity C ( ) Bound to CC5 Binding site Disrupted by C ery low affinity Binding site NOT disrupted by C High affinity Adapted from osley et al. 13th CO 2006; abstract 598.
Antiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationAntiretroviral Treatment (ART) of Adult HIV Infection*
Antiretroviral Treatment (ART) of Adult HIV Infection* Prepared by J Montaner for the BC- CfE Therapeutic Guidelines Committee of the British Columbia - Centre for Excellence in HIV/AIDS. *Based on M Thompson,
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationWOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationTreatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if
More informationHIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
More informationIndustry Request Integrase Inhibitors
Industry Request Integrase Inhibitors The objective of this request is to describe and understand the temporal changes in the prescribing practices of Integrese Inibitors (II) in AHOD cohort between 1/1/
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationHIV - Life cycle. HIV Life Cyle
Human Immunodeficiency Virus Retrovirus - integrated into host genome ne single-strand RA 7,000 bases HIV1 > HIV2 > HIV0 Pathology Destruction of CD4+ T lymphocytes Loss of immune function pportunistic
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za
ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationMedChem 401~ Retroviridae. Retroviridae
MedChem 401~ Retroviridae Retroviruses plus-sense RNA genome (!8-10 kb) protein capsid lipid envelop envelope glycoproteins reverse transcriptase enzyme integrase enzyme protease enzyme Retroviridae The
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationDidactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012
Didactic Series Update: 2012 HIV Treatment Guidelines Daniel Lee, MD August 30, 2012 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine is accredited by the Accreditation Council
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationMedscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationANTIRETROVIRAL THERAPY
ANTIRETROVIRAL THERAPY Editor s Note: Section III: Deciding When to Initiate ART is currently under revision due to recent data in favor of further expanding indications for antiretroviral therapy. What
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationFluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids
Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationHIV epidemiology since HIV in the United States. HIV Transmission
HIV epidemiology since 1999 8% increase in HIV diagnoses Men who have sex with men (MSM) increased 14% Heterosexual increased 10% IVDU decrease about 30% Young Black MSM 15% incidence HIV in the United
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationRisk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf
Risk of HIV-1 low level viremia to treatment failure in the AREVIR-RESINA cohort in Germany Nadine Lübke Düsseldorf FDA Approval of antiretroviral drugs 1980-84 1985-89 1990-94 1995-99 2000-04 2005-09
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationHIV and AIDS. Shan Nanji
HIV and AIDS Shan Nanji HIV 2 Description: Enveloped Positive Sense HIV 3 Structural Genes: Cleavage of gp160 leads to formation of ENV: Gp120: attachment to host CD4 T Cell Gp41: GAG (p24) Capsid protein
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationHIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time
STRATEGIES FOR FIRST LINE HIV THERAPY issues to think about when going on therapy for the first time A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Deciding
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationViral Resistance with Topical RT-Microbicides. Ian McGowan MD PhD FRCP David Geffen School of Medicine Los Angeles
Viral Resistance with Topical RT-Microbicides Ian McGowan MD PhD FRCP David Geffen School of Medicine Los Angeles verview What antiretrovirals (ARV) are being considered as candidate microbicides? How
More informationThe Use of Resistance Testing in HIV
The Use of Resistance Testing in HIV Dushyantha Jayaweera, M.D., M.R.C.O.G., F.A.C.P. Professor in Clinical Medicine Division of Infectious Diseases University of Miami Miller School of Medicine Viral
More informationAntiviral Chemotherapy
Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus
More informationI m B m. 1 f ub I B. D m B. f u. 1 f ua 1 D I A. I A m. D m A. f a. 1 f u. D m B ) D m A )(I m B. 1 f ua. 1 (I m A. log (I A. log f.
Supplementary Material Appendix 1 Here we show that independent inhibition by a single drug of two distinct steps (A and ) in the viral life cycle results in a non-linear median effect dose-response curve
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationClass Review: HIV Antiretroviral Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationQuick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents
Author: Malte Schütz, MD June 1, 2002 Quick Reference Guide to Antiretrovirals Regular updates to this publication are posted on the Medscape Web site at http://hiv.medscape.com/updates/quickguide. Please
More informationC h a p t e r 5 5 HIV Therapy Where are We Now?
C h a p t e r 5 5 HIV Therapy Where are We Now? AK Tripathi Professor of Medicine, Physician & Haemato-Oncologist, King George s Medical College, Lucknow Introduction Human Immunodeficiency Virus type
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More informationIntroduction. Introduction VII. Introduction
HIV Treatment Introduction VII Introduction HIV/AIDS clinical care has improved dramatically over the decades, given the availability of new medications and a better understanding of how best to use antiretrovirals
More informationHIV for the Non-ID Pharmacist
Disclosures HIV for the Non-ID Pharmacist I have nothing to disclose at this time Carmen Faulkner-Fennell, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist--Infectious Diseases Greenville Hospital System
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationAntiviral Agents DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU. 06 August
Antiviral Agents Dr. Yunita Sari Pane, MS DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU 06 August 2009 1 VIRUSES Obligate intracellular parasites Consist of a core genome in a protein shell and some are surrounded
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationHIV & Aging: Evolving Clinical Considerations in the New Millennium
HIV & Aging: Evolving Clinical Considerations in the New Millennium Julian Falutz, MD, FRCP (C) Director, HIV Metabolic Clinic Immunodeficiency Treatment Centre Senior Physician Division of Geriatrics
More informationHIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego
HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationEvaluation and Management of Virologic Failure
National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:
More informationZepatier. (elbasvir, grazoprevir) New Product Slideshow
Zepatier (elbasvir, grazoprevir) New Product Slideshow Introduction Brand name: Zepatier Generic name: Elbasvir, grazoprevir Pharmacological class: HCV NS5A inhibitor + HCV NS3/4A protease inhibitor Strength
More informationThe US Food and Drug Administration has
NEW ANTIRETROVIRAL AGENTS FOR TREATMENT-EXPERIENCED PATIENTS * Roy M. Gulick, MD, MPH ABSTRACT Antiretroviral treatment regimens currently available for the treatment of the human immunodeficiency virus
More informationPHCP 403 by L. K. Sarki
PHCP 403 by L. K. Sarki objectives To gain insight into the epidemiology of HIV To gain basic understanding of the etiology of HIV disease To know the clinical manifestations of the disease To gain a basic
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More information